We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Study Findings Could Lead to a Better Cholesterol Treatment

Study Findings Could Lead to a Better Cholesterol Treatment content piece image
a) A heparin pentasaccharide docked at the electrostatic surface (red negative; blue positive) of the HSPG-binding site in PCSK9 with positively charged amino acids (R: arginine, H: histidine) indicated. b) Superposition of SANORG with PCSK9 (ribbon). Credit: Gustafsen, C., et al. (2017) Nature Communications. doi:10.1038/s41467-017-00568-7
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

More than 600,000 Danes are being treated with cholesterol lowering medicine. 98 per cent of them are treated with statins, which curb the body's own production of cholesterol so that the level of cholesterol falls. However, statins also give rise to the body forming more of a harmful protein - known as PCSK9 - which counters the effect of the statins. New research from Aarhus University has now uncovered the way in which PCSK9 breaks down the LDL receptors, which are a kind of receptor molecule that absorbs the bad LDL cholesterol in the blood into the liver.

This discovery makes it possible to develop potentially more efficient and also cheaper PCSK9 inhibiting medicine, which is the new hope for cholesterol treatment.

"Statins save many lives every year, but the medicine has the unfortunate consequence that the liver cells begin to produce more PSCK9. We have now uncovered how PCSK9 is captured by specific molecules in the liver called heparan sulfate proteoglycans (HSPG), which subsequently lead to the breaking down of the LDL receptor. The consequence is less LDL receptor in the liver, higher LDL cholesterol in the blood and an increased risk of blood clots in the heart. If this process is inhibited, the LDL receptor is protected against degradation, and the amount of cholesterol in the blood falls," says Camilla Gustafsen, who is one of the researchers behind the result and assistant professor at the Department of Biomedicine at Aarhus University.

With the discovery, the researchers have provided one of the pieces that has been missing in the puzzle of understanding PCSK9, and this opens up for the development of a new type of medicine that can potentially work far better than statins.

The research result has just been published in the international scientific journal Nature Communications.

Potential for better and cheaper medicine

PCSK9 inhibiting medicine is already available on the market, but due to high costs it is only offered to patients who are particularly at risk, as well as those who do not have benefit from or are intolerant to statins. Using the new knowledge about PCSK9, the researchers from Aarhus have begun to develop new medicine that is now ready for the first tests on patients.

"The development of PCSK9 inhibitors is one of the biggest biomedical success stories of recent times, and getting basic research translated into medicine has happened extremely quickly thanks to intense research around the world. But there are still aspects of the PSCK9 protein that we do not yet fully understand. The new discovery shows the potential for creating more effective PCSK9 inhibitors than those we have today, and more cheaply, so that they become accessible for many more people in line with statins," says Simon Glerup, who is one of the driving forces behind the research project and associate professor at the Department of Biomedicine at Aarhus University.

The first medicine must first undergo comprehensive testing and will first be available for patients in five years at the earliest.

This article has been republished from materials provided by Aarhus University. Note: material may have been edited for length and content. For further information, please contact the cited source.


Gustafsen, C., Olsen, D., Vilstrup, J., Lund, S., Reinhardt, A., Wellner, N., . . . Glerup, S. (2017). Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nature Communications, 8(1). doi:10.1038/s41467-017-00568-7